Biotechnology
Lilly Details One-Year Taltz and Zepbound PsA Trial Results
Eli Lilly and Company on November 11, 2026 announced detailed exploratory 52-week results from its TOGETHER-PsA Phase 3b trial. At Week 52, 43.7% of patients receiving Taltz (ixekizumab) plus Zepbound (tirzepatide) achieved ACR50, indicating at least a 50% reduction in…
IASO Bio Wins China IND Approval for IASO208 CAR-T Therapy
IASO Bio announced on November 11, 2026, that China’s National Medical Products Administration had approved the investigational new drug (IND) application for IASO208, its CD20-targeting in vivo CAR-T therapy. The approval moves the company’s InTelliCAR platform into synchronized clinical development…
FDA Approves PIMJETMI With Abbisko Milestone Tied to U.S. Sale
EMD Serono announced on November 10, 2026, that the U.S. Food and Drug Administration had approved PIMJETMI (pimicotinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The…
Azenta Q4 Revenue Rises 5% as Sample Management Solutions Grows 9%
Azenta’s fourth-quarter and full-year results, published November 10, 2026, showed revenue from continuing operations rising 5% year over year to $167.1 million for the quarter ended September 30, 2026. Adjusted EBITDA, a company-defined profitability measure, fell 7% to $19.4 million,…
New England Biolabs Launches Mammoth’s MB-CasFire Research Enzyme
On November 10, 2026, New England Biolabs (NEB) announced a global licensing agreement with Mammoth Biosciences to manufacture and commercialize MB-CasFire, making the CRISPR enzyme immediately available worldwide for research use through NEB and its distribution network. NEB’s product listing…
Protalix Q3 Product Sales Rise 23.5% as R&D Costs Climb 55%
Protalix BioTherapeutics reported third-quarter revenue of $21.9 million on November 10, 2026, with product sales up 23.5% as Chiesi drove growth. Net income rose to $4.0 million from $2.4 million despite a 55% increase in research and development spending, while…
Beam Sickle Cell Therapy Meets Pivotal Goals Ahead of Planned BLA
Beam Therapeutics announced on November 10, 2026 that ristoglogene autogetemcel (risto-cel), its investigational one-time cell therapy for sickle cell disease, met the primary efficacy and safety endpoints in a prespecified interim analysis of the BEACON Phase 1/2 trial, supporting a…
Tyra Biosciences Q3 Loss Widens to $51.1 Million as Research Costs Rise
On November 10, 2026, Tyra Biosciences reported third-quarter results showing a $51.1 million net loss for the quarter ended September 30, 2026, compared with $29.9 million in the same period of 2025, as spending increased on three clinical programs for…
Lundbeck Lifts 2026 Outlook as Vyepti Revenue Climbs 45%
H. Lundbeck A/S raised its full-year 2026 revenue and adjusted EBITDA growth guidance on November 10, 2026, after nine-month revenue rose 13% and Vyepti revenue 45%, both at constant exchange rates (CER), with total sales reaching 20.2 billion Danish kroner…
Bayer Wins FDA Approval for Sunharbo to Cut Recurrent Stroke Risk
The U.S. Food and Drug Administration on November 9, 2026 approved Sunharbo (asundexian) 50 mg tablets from Bayer HealthCare Pharmaceuticals for use with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk…
PharmaLogic Signs Lantheus CDMO Deal With Long-Term Supply Agreement
PharmaLogic Holdings Corp. announced the agreement on November 9, 2026, saying it had entered into a definitive agreement to acquire Lantheus Holdings’ contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey, manufacturing facility. Financial terms were not…
Simtra Opens $250 Million-Plus Building H With Vial Line Due in 2027
Simtra BioPharma Solutions announced the November 9, 2026, opening of Building H, a more than $250 million expansion of its Bloomington, Indiana, manufacturing campus. The 153,000-square-foot facility adds prefilled-syringe, vial and lyophilization capabilities for the contract development and manufacturing organization,…
Lilly’s Foundayo Lowers Sleep Apnea Events in Two Phase 3 Trials
Eli Lilly announced on November 9, 2026 that once-daily oral Foundayo (orforglipron) significantly reduced breathing interruptions in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight in two 52-week Phase 3 ATTAIN-OSA trials. Lilly plans to submit the…
Whitehawk Q3 Loss Widens to $21.2 Million as Third ADC Enters Clinic
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million on November 9, 2026, up from $17.7 million a year earlier, and disclosed in its results release that its third antibody-drug conjugate (ADC) program had entered clinical testing. The…
ADC Therapeutics Q3 Product Revenue Totals $21 Million as Loss Narrows
ADC Therapeutics reported third-quarter 2026 results on November 9, 2026, with net product revenue rising to $21.0 million from $15.8 million a year earlier, primarily on higher volume. Net loss narrowed to $25.3 million from $41.0 million as operating expenses…
